Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance

Journal of Viral Hepatitis

Volumn 17, Issue 3, 2010, Pages 171-177

  Cho, S W ^a   Koh, K H ^a   Cheong, J Y ^a   Lee, M H ^a   Hong, S P ^b   Yoo, W D ^b   Kim, S O ^b  

^a Ajou University School of Medicine   (South Korea)

^b GeneMatrix Inc   (South Korea)

Author keywords

Adefovir; Drug resistance; Entecavir; Hepatitis B; Lamivudine

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADENINE; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 75149133722     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01161.x     Document Type: Article

References (29)

1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004 350: 1118 1129.
2. Wright TL, Lau JY. Clinical aspects of hepatitis B virus infection. Lancet 1993 342: 1340 1344.
3. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998 339: 61 68.
4. Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003 124: 105 117.
5. Leung NWY, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001 33: 1527 1532.
6. Liaw YF, Sung JJY, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004 351: 1521 1531.
7. Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003 36: 687 696.
8. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998 27: 628 633.
9. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003 348: 808 816. (Pubitemid 36245757)
10. Schiff ER, Lai CL, Hadziyannis S et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre-and post-liver transplantation patients. Hepatology 2003 38: 1419 1427.
11. Fung SK, Chae HB, Fontana RJ et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006 44: 283 290.
12. Lee YS, Suh DJ, Lim YS et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006 43: 1385 1391.
13. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006 131: 1743 1751.
14. Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of a BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997 41: 1444 1448.
15. Zoulim F. Entecavir: A new treatment option for chronic hepatitis B. J Clin Virol 2006 36: 8 12.
16. Levine S, Hernandez D, Yamanaka G et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerase in vitro. Antimicrob Agents Chemother 2002 46: 2525 2532.
17. Tenney DJ, Rose RE, Baldick CJ et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007 51: 902 911.
18. Colonno RJ, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006 44: 1656 1665.
19. Gish RG, Lok AS, Chang TT et al. Entecavir therapy up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007 133: 1437 1444.
20. Tenney DJ, Pokornowski KA, Rose RE et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2008 2: A88.
21. Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004 48: 3498 3507.
22. Lok AS, Zoulim F, Locarnini S et al. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 2007 46: 254 265.
23. Vileneuve JP, Durantel D, Durantel S et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003 39: 1085 1089.
24. Hong SP, Kim NK, Hwang SG et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 2004 40: 837 844.
25. Chang TT, Gish RG, Hadziyannis SJ et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005 129: 1198 1209.
26. Reijnders JG, de Man RA, Pas SD, Schutten M, Janssen HL. Entecavir: a rescue therapy for chronic hepatitis B patients with a limited virological response to adefovir. Hepatology 2007 46: 660A.
27. Chien R-N, Liaw Y-F, Arkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999 30: 770 774.
28. van Boemmel F, Trojan J, Feucht HH et al. Tenofovir shows limited efficacy in treatment of HBV innfections resistant against adefovir (abstract). Hepatology 2007 46: 664A.
29. Tan J, Degertekin B, Wong SN et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008 48: 391 398.